Renalytix AI plc (RENX)

105.00
0.00(0.00%)
  • Volume:
    80,757
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    105.00 - 105.00

RENX Overview

Prev. Close
105
Day's Range
105-105
Revenue
2.78M
Open
105
52 wk Range
98.2-1,190
EPS
-0.46
Volume
80,757
Market Cap
78.5M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
179,140
P/E Ratio
-
Beta
1.57
1-Year Change
-90.54%
Shares Outstanding
74,760,432
Next Earnings Date
30 Nov 2022
What is your sentiment on Renalytix AI?
or
Market is currently closed. Voting is open during market hours.

Renalytix AI plc News

  • UPDATE 1-UK Stocks-Factors to watch on Oct 27
    • ByReuters-

    Oct 27 (Reuters) - Britain's FTSE 100 (.FTSE) index is seen opening 11 points lower at 5,781, according to financial bookmakers, with futures up 0.19% ahead of cash market...

Renalytix AI plc Company Profile

Renalytix AI plc Company Profile

Employees
54

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellSellSellStrong SellStrong Sell
Technical IndicatorsStrong BuyStrong BuyStrong SellStrong SellStrong Sell
SummaryNeutralNeutralStrong SellStrong SellStrong Sell